Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules

The 4-component vaccine 4CMenB, developed against invasive disease caused by meningococcal serogroup B, is approved for use in infants in several countries worldwide. 4CMenB is mostly used as 3 + 1 schedule, except for the UK, where a 2 + 1 schedule is used, and where the vaccine showed an effective...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Hum Vaccin Immunother
Egile Nagusiak: Biolchi, Alessia, Tomei, Sara, Santini, Laura, Welsch, Jo Anne, Toneatto, Daniela, Gaitatzis, Nikolaos, Bai, Xilian, Borrow, Ray, Giuliani, Marzia Monica, Mori, Elena, Pizza, Mariagrazia
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2019
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6605712/
https://ncbi.nlm.nih.gov/pubmed/30352000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1537756
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak